Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|10291||ETCTN||A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|10296||ETCTN||Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation or PTEN mutation||Adult CIRB - Early Phase Emphasis||Available to Open|
|9706||ETCTN||Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10131||ETCTN||A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel||Adult CIRB - Early Phase Emphasis||Available to Open|
|NRG-GY016||NRG||A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary||Adult CIRB - Late Phase Emphasis||Available to Open|
|10184||ETCTN||Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)||Adult CIRB - Early Phase Emphasis||Available to Open|
|ARST1431||COG||A Randomized Phase 3 Study of Vincristine; Dactinomycin; Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI; Torisel; NSC# 683864; IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)||Pediatric CIRB||Available to Open|
|CALGB-100104||CALGB||A Phase III Randomized; Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813; IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma||Adult CIRB - Late Phase Emphasis||Available to Open|
|PEPN1812||A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND #145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|